[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617329":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":24,"locations":28,"responsibleParty":49,"collaborators":24,"id":53,"slug":24,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":24,"overallStatus":31,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ayahuasca","EXPERIMENTAL","oral ayahuasca",[13],"Drug: Ayahuasca",{"label":15,"type":16,"description":17,"interventionNames":18},"esketamine","ACTIVE_COMPARATOR","oral esketamine",[19],"Drug: Esketamine",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":26,"description":17,"armGroupLabels":27,"otherNames":24},"Esketamine",[15],[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hospital das Clínicas da FMRP-USP","RECRUITING","Ribeirão Preto","São Paulo","14049900","Brazil","BR",{"type":38,"coordinates":39},"Point",[40,41],-47.81028,-21.1775,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":24,"email":48},"Rafael Guimarães Santos","CONTACT","5516997721969","banisteria@gmail.com",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Rafael Guimarães dos Santos","PhD","100617329",false,"NCT07317206","Ayahuasca, Esketamine and PTSD","Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study","Inclusion Criteria:\n\n* posttraumatic stress disorder\n\nExclusion Criteria:\n\n* psychiatric and other medical comorbidities","ALL","18 Years","65 Years",{"count":63,"type":64},10,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.",[70],"Posttraumatic Stress Disorder (PTSD)","2025-12-19",{"date":73,"type":74},"2026-01-05","ACTUAL",{"date":76,"type":74},"2025-12-20",{"date":78,"type":64},"2026-07",{"name":5,"class":6},1]